Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 3 Regulation of TGF-β1/Smad signalling by microRNAs (miRs) in tissue fibrosis Figure 3 | Regulation of TGF-β1/Smad signalling by microRNAs (miRs)

Published byUtami Tan Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 3 Regulation of TGF-β1/Smad signalling by microRNAs (miRs) in tissue fibrosis Figure 3 | Regulation of TGF-β1/Smad signalling by microRNAs (miRs)"— Presentation transcript:

1 Figure 3 Regulation of TGF-β1/Smad signalling by microRNAs (miRs) in tissue fibrosis
Figure 3 | Regulation of TGF-β1/Smad signalling by microRNAs (miRs) in tissue fibrosis. Numerous miRs have been implicated in the regulation of tissue fibrosis, particularly kidney fibrosis. miRs are grouped as having an antifibrotic effect (purple), profibrotic effect (pink) or both profibrotic and antifibrotic effects (blue). Whether TGF-β1/Smad3 signalling positively or negatively regulates the transcription of these miRs is indicated, and the target genes inhibited by the miRs are shown. Meng, X.-m. et al. (2016) TGF-β: the master regulator of fibrosis Nat. Rev. Nephrol. doi: /nrneph

Download ppt "Figure 3 Regulation of TGF-β1/Smad signalling by microRNAs (miRs) in tissue fibrosis Figure 3 | Regulation of TGF-β1/Smad signalling by microRNAs (miRs)"

Similar presentations

Tyrosine kinase signalling (review) TGF signalling Notch signalling.

Tyrosine kinase signalling (review) TGF signalling Notch signalling.
Figure. Schematic illustration on chitotriosidase (CHIT1) regulation of TGF-β pathway. CHIT1 enhances the effect of TGF-β through the induction of TGF-β.

Figure. Schematic illustration on chitotriosidase (CHIT1) regulation of TGF-β pathway. CHIT1 enhances the effect of TGF-β through the induction of TGF-β.
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.

Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.
Figure 2 Crosstalk between TGF-β/Smad and other pathways in tissue fibrosis Figure 2 | Crosstalk between TGF-β/Smad and other pathways in tissue fibrosis.

Figure 2 Crosstalk between TGF-β/Smad and other pathways in tissue fibrosis Figure 2 | Crosstalk between TGF-β/Smad and other pathways in tissue fibrosis.
Figure 6 Effects of adiponectin on podocyte function

Figure 6 Effects of adiponectin on podocyte function
Figure 3 Energy metabolism regulation, cardiovascular and bone disease in CKD Figure 3 | Energy metabolism regulation, cardiovascular and bone disease.

Figure 3 Energy metabolism regulation, cardiovascular and bone disease in CKD Figure 3 | Energy metabolism regulation, cardiovascular and bone disease.
Figure 4 Expression of coagulation protease receptors in renal cells

Figure 4 Expression of coagulation protease receptors in renal cells
Figure 4 Interactions between adipose, the microbiome and kidney

Figure 4 Interactions between adipose, the microbiome and kidney
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Figure 1 Mechanisms of kidney injury in the setting of obesity

Figure 1 Mechanisms of kidney injury in the setting of obesity
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Figure 1 Role of the kidney in glucose homeostasis

Figure 1 Role of the kidney in glucose homeostasis
Figure 1 Model of mechanosensation through primary cilia

Figure 1 Model of mechanosensation through primary cilia
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Figure 1 Monogenic forms of diabetes mellitus

Figure 1 Monogenic forms of diabetes mellitus
Figure 6 The bioavailability of phosphate differs according to the protein source Figure 6 | The bioavailability of phosphate differs according to the.

Figure 6 The bioavailability of phosphate differs according to the protein source Figure 6 | The bioavailability of phosphate differs according to the.
Figure 7 The efficacy of phosphate-binder therapy

Figure 7 The efficacy of phosphate-binder therapy
Figure 3 Putative actions of glucagon-like peptide 1 (GLP-1)

Figure 3 Putative actions of glucagon-like peptide 1 (GLP-1)

Similar presentations

Ads by Google